Binance Wallet Launches Alpha Earn Hub Amid Record $12.5B Daily Volume
The introduction of the hub comes as Binance Wallet surpassed $12.5 billion in daily on-chain volume, a record high spurred by increased activity around Binance Alpha, a platform that which hosts token launches and airdrops.
'Reaching a new all-time high of $12.5 billion in daily on-chain trading volume reflects the growing demand from users actively engaging with Binance Alpha on Binance Wallet,' said Winson Liu, Global Lead of Binance Wallet.
The recent release also means that liquidity providers will also earn points for managing positions on decentralized exchange PancakeSwap, which accessed via the Binance Alpha Earn Hub.
Points can be used to increase allocation of newly-issued tokens and will all eventually be converted into token airdrops.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
an hour ago
- Los Angeles Times
Cafeteria Raises $3-Million Growth Round to Expand Gen Z Insights
Cafeteria, a consumer insights platform that enables Gen Z and Alpha to earn for direct and private brand insights, announced a $3-million growth round, valuing the company at $22 million. The round adds participation from Marquee Ventures, Listen Ventures and Thayer Investment Partners. With the new capital, it is set to expand AI capabilities and scale data infrastructure to transform unstructured text and voice into actionable insights. 'We are reimagining the relationship between Generation Next and brands by delivering them a platform for work and private insights software for clients. Our text and voice data are compounding, and we are investing in AI capabilities that are truly in-context of the generation,' said Rishi Malhotra, chief executive and co-founder of Cafeteria, in a statement. Since January, the company has more than doubled its userbase and tripled the volume of insights produced. Brands across fashion, beauty and consumer goods are utilizing its teen-to-brand operating system and enterprise software for authentic Gen Next intelligence. Brand partners include category leaders across beauty, retail and consumer goods. Cafeteria previously raised a multimillion-dollar seed round in July 2024, led by Collaborative Fund and Imaginary Ventures, with additional participation from Bertelsmann and music mogul Guy Oseary, that valued the company at $12 million. Information for this article was sourced from Cafeteria.
CNBC
a day ago
- CNBC
Firefly Aerospace lifts IPO range that would value company at over $6 billion
Firefly Aerospace has lifted the share price range for its upcoming initial public offering in a move that would value the space technology company at over $6 billion. The lunar lander and rocket maker said in a filing Monday that it expects to price shares in its upcoming IPO between $41 and $43 apiece. Firefly's new target range would raise nearly $697 million at the top end of the range. That's up from the previously expected $35 to $39 price per share that Firefly announced in a filing last week, which targeted a $5.5 billion valuation. Firefly announced plans to go public last month as interest in space technology gains steam, and billionaire-led companies such as Elon Musk's SpaceX rake in more funding. The industry has also begun testing the public markets after a long hiatus in IPO deal activity, with space tech firm Voyager debuting in June. Firefly makes rockets, space tugs and lunar landers, and is widely known for its satellite launching rockets known as Alpha. The company has partnered with major defense players such as Lockheed Martin, L3Harris and NASA, and received a $50 million investment from defense contractor Northrop Grumman. Firefly's revenues jumped from $8.3 million a year ago to $55.9 million at the end of March, the company said. Its net loss grew to $60.1 million, from $52.8 million a year ago.
Business Wire
a day ago
- Business Wire
Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the second quarter on August 14, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: Participant Listening: 1-877-407-9039 or 1-201-689-8470 or - Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. Call me™ link will be made active 15 minutes prior to scheduled start time. The live audio webcast will be accessible here: A replay of the earnings call is available after the conference call has ended. Replay Dial-In: 1-844-512-2921 or 1-412-317-6671 Access ID: 13754595 Replay webcast: About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury ('mTBI'), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ZUNVEYL's active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.] Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'objective,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'target,' 'seek,' 'contemplate,' 'continue' and 'ongoing,' or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company's intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company's filings with Canadian securities regulatory authorities and available at and the Company's filings with the United States Securities and Exchange Commission (the 'SEC'), including those risk factors under the heading 'Risk Factors' in the Company's [ Form S-1/A registration statement as filed with the SEC on November 6, 2024 and available at ] These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.
